

1 18. The tumor cell composition according to claim 17, wherein said at least one
2 additional immune modulator is a cytokine protein.

1 19. The tumor cell composition according to claim 18, wherein said cytokine protein
2 is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin
3 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony
4 stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.

1 20. The tumor cell composition according to claim 18, wherein said cytokine protein
2 is granulocyte-macrophage colony stimulating factor.

1 21. An expression vector comprising a polynucleotide sequence encoding a B7-2
2 protein and at least one additional immune modulating protein, or a functional fragment of
3 said B7-2 protein or said immune modulator.

1 22. The expression vector according to claim 21, wherein said at least one additional
2 immune modulating protein is a cytokine protein.

1 23. The expression vector according to claim 22, wherein said cytokine protein is
2 selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin
3 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony
4 stimulating factor, interferon-gamma, and tumor necrosis factor-alpha.

1 24. The expression vector according to claim 22, wherein said cytokine protein is
2 granulocyte-macrophage colony stimulating factor.

1 25. The expression vector according to claim 21, wherein said expression vector is
2 a viral vector.

1 26. The expression vector according to claim 25, wherein said viral vector is a
2 retroviral vector.

1 27. The expression vector according to claim 25, wherein said viral vector is an
2 adenoviral vector.

1 28. The expression vector according to claim 21, wherein said expression vector is
2 encapsulated by, or complexed with, a liposome.

Al
ant
1 29. A method for the treatment or prevention of cancer comprising:
2 a) providing a polynucleotide encoding a B7-2 protein and at least one
3 additional immune modulator, or a functional fragment of said B7-2 protein
4 or said immune modulator;
5 b) transferring said polynucleotide into cancer cells under conditions such that
6 said B7-2 protein and said immune modulator are expressed by at least a
7 portion of said cancer cells; and
8 c) administering an effective amount of the modified cancer cells of step b) to
9 a patient.

1 30. The method according to claim 29 further comprising irradiating said cancer cells
2 expressing said B7-2 protein and said immune modulator prior to administering said
3 irradiated cancer cells into said patient.

1 31. The method according to claim 30, further comprising introducing at least one
2 additional dose of irradiated cancer cells expressing said B7-2 protein and said immune
3 modulator into said immunized subject.

1 32. The method according to claim 29, wherein said at least one additional immune
2 modulator is a cytokine protein.

1 33. The method according to claim 32, wherein said cytokine protein is selected from
2 the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin
3 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor,
4 interferon-gamma, and tumor necrosis factor-alpha.

Al
CNG
1 34. The method according to claim 32, wherein said cytokine protein is granulocyte-
2 macrophage colony stimulating factor.

1 35. The method according to claim 29, wherein said polynucleotide is transferred by
2 a viral vector.

1 36. The method according to claim 35, wherein said viral vector is a retroviral
2 vector.

1 37. The method according to claim 35, wherein said viral vector is an adenoviral
2 vector.

1 38. The method according to claim 29, wherein said polynucleotide is encapsulated
2 by, or complexed with, a liposome.

1 39. The method according to claim 29, wherein said cancer cells are from a solid
2 tumor.

1 40. The method according to claim 29, wherein said cancer cells are from a brain
2 tumor.

1 41. The method according to claim 40, wherein said brain tumor is a glioblastoma.

1 42. The method according to claim 29, wherein said cancer cells are from a
2 melanoma.

1 43. A method for the treatment or prevention of cancer comprising administering to
2 a subject in need thereof an effective amount of a tumor vaccine comprising a tumor cell
3 modified to express a B7-2 protein and at least one additional immune modulator, or a
4 functional fragment of said B7-2 protein or said immune modulator.

1 44. The method according to claim 43, wherein said at least one additional immune
2 modulator is a cytokine protein.

1 45. The method according to claim 44, wherein said cytokine protein is selected from
2 the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin
3 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor,
4 interferon-gamma, and tumor necrosis factor-alpha.

1 46. The method according to claim 43, wherein said cytokine protein is granulocyte-
2 macrophage colony stimulating factor.

1 47. The method according to claim 43, wherein said cancer cells are from a tumor.

1 48. The method according to claim 43, wherein said cancer cells are from a brain
2 tumor.

As Cont 1 49. The method according to claim 48, wherein said brain tumor is a glioblastoma.

1 50. The method according to claim 43, wherein said cancer cells are from a
2 melanoma.
